Anti-tumor immune cells such as CD8+ T cells and regulatory T cells (Tregs) were downregulated in the high-risk group, whereas cancer-promoting cells such as M2 macrophages were upregulated in the high-risk group (Figure 6D), which indicated that patients with BC in the high-risk group had anti-cancer immune deficiency. The gene discussed is CD8A; the disease is cancer.